Reuters

XTL in $108 mln licensing deal for hep C program

March 20 (Reuters) - XTL Biopharmaceuticals Ltd said it signed a $108 million deal licensing its pre- clinical hepatitis C program to San-Francisco based private biotechnology firm Presidio ...
Reuters

XTL in $108 mln licensing deal for pre-clinical hep C program

March 20 (Reuters) - XTL Biopharmaceuticals Ltd said it signed a $108 million deal licensing its pre- clinical program in hepatitis C to San-Francisco based private biotechnology firm Presidio ...